

Small/Mid Cap Factors: a PM's Guide

Fundamentals in focus; Value could work next

Small Cap

Best strategy YTD? Buying + revisions/selling - revisions

The fundamental outlook for small caps has mattered more than other factors this year: Russell 2000 stocks with the most positive estimate revisions have outperformed those with the most negative revisions by 10ppt YTD – the widest spread among all factors we track. Earnings Surprise was also among the top long and long-short factors. Small caps saw a better-than-expected earnings season, with profits continuing to recover (-12% YoY vs. -14% in 3Q and -21% in 2Q) and coming in 3% better than expected, though with weak forward guidance (which we've seen across the cap spectrum). We continue to expect earnings to be a bigger driver of returns than multiple expansion this year (see: SMID Valuations). Note that our Estimate Revision factor has historically performed best in environments similar to today: when the overall Earnings Revision ratio for small caps is still negative but improving (Exhibit 3).

Regime Indicator back in Recovery: how to position

Our team's US Regime Indicator improved for a second month, putting it officially back in the "Recovery" phase (see: Quantitative Profiles). Historically, recoveries have lasted eight months on avg., but ranged from 3-14 months. If this Recovery is sustainable, the shift is most supportive for Value factors within small caps (with Operating Cash Flow/ Price the best-performing long and long-short factor); Cash Return factors have also typically outperformed in this phase. Factors which have historically lagged most in Recoveries include stocks with high short interest ratios, GARP (low PEG ratio) stocks and secular growth stocks (High Long-Term Growth). And while Quality factors have seen mixed results in this phase (50/50 hit rate both long and long-short), we would stick with higher quality SMID caps (avoid non-earners with duration risk).

Liquidity & Risk factors led last month

Amid a strong month for the index (eq. wtd. Russell 2000 +5.0%), only half of the long (Quintile 1) factors we track led the index, and only three long-short factors saw better returns. Liquidity and Risk factors were the top long and long-short factors, led by 3M Avg. Daily Volume (Liquidity), 1M Trading Volume (Liquidity) and 1yr Price Volatility (Risk). Value factors saw the weakest performance last month, and also struggled in large caps (see Quantitative Profiles note linked above) – but less-muddled signals from our US Regime Indicator going forward could help.

Screen of the month: stocks for a Recovery

Given the official move in the US Regime Indicator to "Recovery", we include an updated screen of Buy-rated Russell 2000 stocks that rank well on "Recovery" factors (including Value & Cash Return), including a Quality overlay (given views above) and excluding stocks with high short interest (worst "Recovery" factor). See Exhibit 4.

Trading ideas and investment strategies discussed herein may give rise to significant risk and are not suitable for all investors. Investors should have experience in relevant markets and the financial resources to absorb any losses arising from applying these ideas or strategies.

BofA Securities does and seeks to do business with issuers covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Refer to important disclosures on page 20 to 22.

12671984

18 March 2024


Small Cap Research United States

Jill Carey Hall, CFA Equity & Quant Strategist BofAS +1 646 855 3327 jill.carey@bofa.com

Nicolas Woods Equity & Quant Strategist BofAS +1 646 556 4179 nicolas.woods_barron@bofa.com

Exhibit 1: Russell 2000 top 5/bottom 5 factors by Q1-Q5 spreads in Feb. (ppt) Price Volatility (1yr) best; Forward E/P

Price Volatility (1yr) best; Forward E/P worst




Source: FactSet, BofA US Equity & Quant Strategy

BofA GLOBAL RESEARCH

Exhibit 2: Russell Midcap top 5/bottom 5 factors by Q1-Q5 spreads in Feb. (ppt)


30wk/75wk MA best; Book/Price worst



Source: FactSet, BofA US Equity & Quant Strategy
BofA GLOBAL RESEARCH

Exhibit 3: The outperformance of small cap stocks with the most positive estimate revisions vs. those with the most negative revisions has been strongest when the earnings revision ratio is still negative but improving (the case today)

Long-short (Q1-Q5) performance spread of Russell 2000 Estimate Revisions factor based on overall small cap earnings revision ratio phase (2001-2/2024)



Source: FactSet, BofA US Equity & US Quant Strategy

Note: Earnings revision ratio based on # of S&P600 stocks with upward revisions to consensus estimates / # of stocks with downward revisions to consensus estimates over a trailing 3-month period.

BofA GLOBAL RESEARCH

Screen of the month: Small caps for a shift to Recovery

Below we include a screen of Russell 2000 stocks based on the following criteria (liquidity metrics provided for reference):

- Value: top quintile of the index on either CFO/P, EBITDA/EV, Sales/EV, Book/Price or FCF/EV (top 5 Value factors in Early Cycle regimes since 1991).
- Cash return: dividend payer or buying back shares in last 12 mos. (where Cash Return has been one of the best-performing "Recovery" styles since 1991).
- Excludes non-earners and excludes top quintile of the index on Short Interest (SI) Ratio (worst performing factor in Early Cycle regimes since 1991).

D - £A

Buy-rated by BofA fundamental analysts.

Exhibit 4: Small caps for a Recovery/Early Cycle regime screen

Buy-rated Russell 2000 stocks that rank well on Early Cycle factors/avoid factors that do poorly Early Cycle (see criteria above) plus a Quality overlay

			BofA		3m avg. daily	CFO/P	EBITDA			FCF/	Dividend	Share	SI
Ticker	Company Name	Sector	Rating	Price	\$ volume	(LTM)	/EV	Sales/EV	Book/Price	EV	Payer?	Repurchase	Ratio
MODG	Topgolf Callaway Brands Corp.	Cons. Disc.	BUY	13.91	45.90	0.06	8.11	65.36	1.50	-0.06	NONPAYER	-0.16	6.88
UPBD	Upbound Group, Inc.	Cons. Disc.	BUY	33.20	13.70	0.15	49.01	121.31	0.32	0.07	PAYER	-5.00	5.00
VC	Visteon Corporation	Cons. Disc.	BUY	114.53	33.24	0.11	11.87	126.77	0.23	0.07	NONPAYER	-0.71	3.22
ADNT	Adient plc	Cons. Disc.	BUY	32.58	34.66	0.22	17.46	299.70	0.70	0.08	NONPAYER	-1.22	5.64
KNTK	Kinetik Holdings Inc. Class A	Energy	BUY	36.66	13.38	0.28	7.44	13.55	-0.44	0.03	PAYER	26.55	3.91
TNK	Teekay Tankers Ltd. Class A	Energy	BUY	55.77	27.13	0.34	36.38	75.76	0.76	0.34	PAYER	0.51	1.44
AESI	Atlas Energy Solutions Inc.	Energy	BUY	21.93	13.63	0.12	11.92	22.34	-0.07	80.0	PAYER	-87.35	5.66
PTEN	Patterson-UTI Energy, Inc.	Energy	BUY	11.54	76.66	0.18	16.85	55.41	1.00	0.05	PAYER	92.46	2.97
GRNT	Granite Ridge Resources, Inc.	Energy	BUY	6.25	3.34	0.31	32.36	44.63	0.79	0.28	PAYER	N/A	6.24
FBP	First Bancorp	Financials	BUY	16.49	21.14	N/A	N/A	N/A	0.44	N/A	PAYER	-6.37	3.64
NMIH	NMI Holdings, Inc. Class A	Financials	BUY	30.01	15.39	N/A	N/A	N/A	0.73	N/A	NONPAYER	-2.58	2.14
ESNT	Essent Group Ltd.	Financials	BUY	55.33	27.02	N/A	N/A	N/A	0.84	N/A	PAYER	-0.75	1.47
VCTR	Victory Capital Holdings, Inc. Class A	Financials	BUY	40.16	13.72	N/A	N/A	N/A	0.42	N/A	PAYER	-3.75	4.02
PAGS	PagSeguro Digital Ltd. Class A	Financials	BUY	13.91	37.71	N/A	N/A	N/A	0.58	N/A	NONPAYER	-2.48	3.72
CODI	Compass Diversified Holdings	Financials	BUY	23.56	4.33	N/A	N/A	N/A	0.51	N/A	PAYER	-0.53	4.64
ACT	Enact Holdings Inc	Financials	BUY	29.33	8.99	N/A	N/A	N/A	1.00	N/A	PAYER	-1.75	2.81
PDCO	Patterson Companies Incorporated	Health Care	BUY	27.22	34.94	-0.29	12.19	212.16	0.41	-0.26	PAYER	-3.05	3.44
HEES	H&E Equipment Services, Inc.	Industrials	BUY	57.95	10.65	0.18	18.44	39.61	0.24	-0.09	PAYER	0.39	2.72
IDCC	InterDigital, Inc.	Tech	BUY	102.59	45.25	0.22	16.54	24.61	0.21	0.26	PAYER	-12.43	8.52
OI	O-I Glass Inc	Materials	BUY	15.56	28.77	0.31	21.32	104.72	0.76	0.02	NONPAYER	-0.26	3.24
CMC	Commercial Metals Company	Materials	BUY	53.93	50.41	0.20	18.88	123.96	0.67	0.10	PAYER	-0.50	4.52
PTVE	Pactiv Evergreen, Inc.	Materials	BUY	13.08	5.96	0.24	16.87	90.64	0.49	0.06	PAYER	0.37	2.34
SLVM	Sylvamo Corporation	Materials	BUY	56.78	19.32	0.22	19.73	112.32	0.33	0.10	PAYER	-5.68	1.36
PNM	PNM Resources, Inc.	Utilities	BUY	36.70	62.30	0.17	8.65	25.14	0.71	-0.06	PAYER	0.00	2.06

2--- --- J-:L- CEO/D EDITOA

Source: FactSet, BofA US Equity & US Quant Strategy Note: This screen is not a recommended list either individually or as a group of stocks. Investors should consider the fundamentals of the companies and their own individual circumstances/objectives before making any investment decisions. Prices as of close 03/15/23.

BofA GLOBAL RESEARCH


ECE! Dividend Chans



Style performance in US regimes

Our team's US Regime Indicator (see <u>Quantitative Profiles</u> report and the Appendix of this report for details) aggregates top-down variables that capture earnings and economic growth expectations, inflation, credit conditions, and other variables to yield four phases (charts below). The indicator (which is based on smoothed 3mo. data) improved for the second month in February, confirming its Recovery phase. To complement our work within large caps, we analyzed small-cap style performance during each phase of the cycle, below. Value has typically led in Recovery phases while Quality outperforms in Downturns; Cash Return strategies typically outperform in both phases.


Exhibit 5: US Regime Indicator improved in Feb., now back in Recovery US Regime Indicator, 1/970-2/2024



Source: BofA US Equity & US Quant Strategy, Refinitiv, ICE Data Indices, LLC, ISM Federal Reserve, Bureau of Labor Statistics. See Appendix for Methodology. Disclaimer: The indicator identified as US Regime Indicator above is intended to be an indicative metric only and may not be used for reference purposes or as a measure of performance for any financial instrument or contract, or otherwise relied upon by third parties for any other purpose, without the prior written consent of BofA Global Research. This indicator was not created to act as a benchmark.

BofA GLOBAL RESEARCH

Exhibit 6: Recovery: Value, Small Size, High Risk tend to fare well US Regimes – a heuristic



Source: BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Exhibit 7: Value has historically performed best in Early Cycle

Small-cap factor group performance during phases of our US Regime Indicator (January 1990-present; back-tested)

		Valuation	Quality	Liquidity	Growth	Risk	Momentum	Leverage	Cash Deployment	Size
Early Cycle	Median	12%	1%	-1%	2%	1%	0%	-3%	2%	-3%
	Hit Rate	88%	50%	50%	63%	63%	50%	38%	75%	25%
Mid Cycle	Median	4%	2%	2%	4%	5%	2%	1%	-4%	-2%
-	Hit Rate	63%	75%	63%	75%	75%	75%	88%	25%	50%
Late Cycle	Median	0%	7%	0%	0%	-10%	0%	1%	6%	3%
	Hit Rate	44%	100%	56%	56%	11%	78%	67%	78%	89%
Recession	Median	-1%	3%	1%	0%	-7%	5%	-2%	4%	3%
	Hit Rate	43%	71%	57%	43%	29%	71%	43%	71%	71%
Quintile 5 vs. Inde	ex									
		Valuation	Quality	Liquidity	Growth	Risk	Momentum	Leverage	Cash Deployment	Size
Early Cycle	Median	-9%	-7%	-6%	-1%	-3%	4%	-2%	-2%	-2%
	Hit Rate	38%	38%	25%	38%	38%	50%	50%	25%	50%
Mid Cycle	Median	1%	3%	-6%	0%	-6%	-3%	2%	0%	-2%
	Hit Rate	50%	63%	0%	38%	13%	13%	63%	38%	25%
Late Cycle	Median	-9%	-13%	-2%	-7%	8%	-12%	-5%	-1%	-9%
	Hit Rate	11%	0%	22%	11%	67%	0%	33%	22%	0%
Recession	Median	-3%	-7%	-4%	-4%	6%	-10%	-4%	-3%	-5%
	Hit Rate	43%	14%	14%	14%	86%	0%	29%	14%	14%
Quintile 1-Quinti	le 5									
		Valuation	Quality	Liquidity	Growth	Risk	Momentum	Leverage	Cash Deployment	Size
Early Cycle	Median	20%	4%	5%	4%	4%	-6%	5%	6%	-1%
	Hit Rate	88%	50%	75%	63%	63%	50%	75%	75%	50%
Mid Cycle	Median	4%	-4%	8%	6%	12%	7%	-2%	-6%	3%
	Hit Rate	50%	38%	88%	75%	75%	88%	38%	13%	63%
Late Cycle	Median	13%	19%	2%	7%	-19%	13%	2%	8%	17%
	Hit Rate	89%	100%	56%	100%	11%	100%	89%	78%	100%
Recession	Median	2%	7%	3%	7%	-12%	15%	2%	7%	10%
	Hit Rate	71%	86%	71%	86%	14%	100%	57%	86%	71%

Note: Hit rate = % of periods in which style outperformed the equal-weighted Russell 2000. For complete definitions of our factors, please see the Appendix. Back-tested performance is hypothetical in nature and reflects application of the screen and is not intended to be indicative of future performance. Back-tested performance here is the annualized performance during each regime of the US Regime Indicator from January 1990 through the present, based on our top quintile factors of the Russell 2000. **Source:** FactSet financial data and analytics, BofA US Equity & US Quant Strategy



Early Cycle factor playbook for small-cap investors

We show the best- and worst-performing factors – both long (Q1) and long-short (Q1-Q5) – during Recovery/Early Cycle periods of our US Regime Indicator. Value factors, such as CFO/P (LTM) and Sales/Price, were among the best long-short and long factors; EBITDA/EV was also a top long factor. Leverage and Short Interest factors fared poorly.

Exhibit 8: Top small-cap long factors (Q1 versus index) in Early Cycle (Back-tested)

Annualized performance (Q1-Russell 2000 equal-wtd index) and hit rates of top 15 Russell 2000 factors during Early Cycle regimes since 1990

Q1 vs. Index

Factor	Category	Avg	Median	Hit Rate
CFO/P (LTM)	Valuation	29%	19%	88%
EBITDA/EV	Valuation	17%	11%	88%
Sales/EV	Valuation	17%	12%	88%
Book/Price	Valuation	16%	6%	88%
FCF Yield	Valuation	16%	11%	88%
Forward E/P	Valuation	16%	10%	88%
Trailing E/P	Valuation	11%	9%	88%
FCF/EV	Valuation	10%	9%	88%
FY1/FY0 Growth	Growth	5%	3%	88%
Sales/Price	Valuation	28%	15%	75%
Net Debt/Mkt Cap	Leverage	20%	13%	75%
Cumulative trading volume (-1m)	Liquidity	7%	5%	75%
3M Avg Daily Volume	Liquidity	6%	2%	75%
Dividends: Nonpayer-Payer	Cash Deployment	1%	2%	75%
1M Change 200 Day MA	Momentum	-4%	4%	75%

Source: FactSet, BofA US Equity & US Quant Strategy. Avg = average.

Note: Hit rate = % of periods in which Q1 outperformed Q5. For complete definitions of our factors, please see the Appendix. Back-tested performance is hypothetical in nature and reflects application of the screen and is not intended to be indicative of future performance. Back-tested performance here is the annualized performance during each regime of the US Regime Indicator from January 1990 through the present, based on our top quintile factors of the Russell 2000.

BofA GLOBAL RESEARCH

Exhibit 10: Bottom small cap long factors (Q1 versus index) in Early Cycle (Back-tested)

Annualized performance (Q1-Russell 2000 equal-wtd index) and hit rates of bottom 15 Russell 2000 factors during Early Cycle regimes since 1990

Factor	Category	Avg	Median	Hit Rate
SI Ratio	Miscellaneous	-12%	-10%	0%
Net Debt/EBITDA Adj.	Leverage	-12%	-12%	0%
Net Debt/EBITDA	Leverage	-9%	-9%	0%
Forward PEG	GARP	-8%	-5%	13%
3M Avg Daily \$ Volume	Liquidity	-8%	-8%	13%
Short interest 12m z-score	Miscellaneous	-8%	-8%	14%
Market Cap	Liquidity	-7%	-2%	25%
IBES Mean LT Growth	Growth	-3%	-7%	25%
Closing Price	Miscellaneous	-7%	-5%	38%
12M Price Change	Momentum	-7%	0%	38%
YoY Change in Trailing EPS	Growth	-5%	-3%	38%
Operating Margin Expansion	Growth	-4%	-5%	38%
Return on Avg Assets LTM	Quality	-4%	-2%	38%
3M Price Chg	Momentum	-3%	-2%	38%
ROE	Quality	-1%	-4%	38%

Source: FactSet, BofA US Equity & US Quant Strategy

Note: Hit rate = % of periods in which Q1 outperformed Q5. For complete definitions of our factors, please see the Appendix. Back-tested performance is hypothetical in nature and reflects application of the screen and is not intended to be indicative of future performance. Back-tested performance here is the annualized performance during each regime of the US Regime Indicator from January 1990 through the present, based on our top quintile factors of the Russell 2000.

BofA GLOBAL RESEARCH

Exhibit 9: Top small-cap long-short factors (Q1-Q5) in Early Cycle (Back-tested)

Annualized performance (Q1-Q5 spreads and hit rates) of top 15 Russell 2000 factors during Early Cycle regimes since 1990

Q1-Q5

Factor	Category	Avg	Median	Hit Rate
CFO/P (LTM)	Valuation	34%	43%	88%
Sales/Price	Valuation	33%	30%	88%
Book/Price	Valuation	20%	21%	88%
EBITDA/EV	Valuation	18%	24%	88%
FCF Yield	Valuation	11%	24%	88%
Sales/EV	Valuation	21%	25%	75%
Cumulative trading volume (-1m)	Liquidity	20%	14%	75%
Net Debt/Mkt Cap	Leverage	19%	27%	75%
3M Avg Daily Volume	Liquidity	16%	11%	75%
Trailing EG/P	GARP	16%	13%	75%
5Yr Beta	Risk	15%	1%	75%
FCF/EV	Valuation	9%	11%	75%
Net Debt/Equity	Leverage	7%	13%	75%
Forward E/P	Valuation	6%	17%	75%
Share Repurchase	Cash Deployment	6%	16%	75%

Source: FactSet, BofA US Equity & US Quant Strategy

Note: Hit rate = % of periods in which Q1 outperformed Q5. For complete definitions of our factors, please see the Appendix. Back-tested performance is hypothetical in nature and reflects application of the screen and is not intended to be indicative of future performance. Back-tested performance here is the annualized performance during each regime of the US Regime Indicator from January 1990 through the present, based on our top quintile factors of the Russell 2000.

BofA GLOBAL RESEARCH

Exhibit 11: Bottom small cap long-short factors (Q1-Q5) in Early Cycle (Back-tested)

Annualized performance (Q1-Q5 spreads and hit rates) of bottom 15 Russell 2000 factors during Early Cycle regimes since 1990

Factor	Category	Avg	Median	Hit Rate
SI Ratio	Miscellaneous	-22%	-17%	0%
Forward PEG	GARP	-22%	-10%	13%
Net Debt/EBITDA	Leverage	-20%	-14%	13%
Net Debt/EBITDA Adj.	Leverage	-14%	-12%	13%
Short interest 12m z-score	Miscellaneous	-14%	-13%	14%
IBES Mean LT Growth	Growth	-8%	-9%	25%
Trailing 5 Year Sales Growth	Growth	-5%	-10%	25%
Trailing 5 Year EPS Growth	Growth	0%	-4%	25%
ROE	Quality	-10%	-3%	38%
3M Avg Daily \$ Volume	Liquidity	-10%	-11%	38%
1Yr Daily Price Volatility	Risk	14%	-3%	38%
Earnings Surprise	Growth	-4%	-3%	43%
12M Price Change	Momentum	-26%	-4%	50%
9M price change	Momentum	-24%	-7%	50%
Avg 1m & 12m price return rank	Momentum	-23%	-10%	50%

Source: FactSet, BofA US Equity & US Quant Strategy

Note: Hit rate = % of periods in which Q1 outperformed Q5. For complete definitions of our factors, please see the Appendix. Back-tested performance is hypothetical in nature and reflects application of the screen and is not intended to be indicative of future performance. Back-tested performance here is the annualized performance during each regime of the US Regime Indicator from January 1990 through the present, based on our top quintile factors of the Russell 2000.




Small cap factor performance

Last month

Exhibit 12: Q1 total returns (%) – 1m (2/29/24)

Best: Price Volatility (1yr) Worst: Dividend Yield (Payers Only)



Source: FactSet, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Exhibit 13: Q5 total returns (%) – 1m (2/29/24)

Best: Low Cash Flow ROIC Worst: Low 3M Avg Daily
Volume




Exhibit 14: Q1-Q5 total returns (%) – 1m (2/29/24) Best: Price Volatility (1yr) Worst: Forward E/P

-20 -15 -10 -5 0 5 10 15 Price Volatilty (1vr) 3M Avg Daily Volume 1M Trading Volume (Cumulative) **EPS Estimate Revision** Russell 2000 (EW) Analyst Coverage Short Interest 12M Z-Score Trailing YoY EPS Growth Earnings Surprise Short Interest Ratio Trailing 5 Year Sales Growth FY1 EPS Growth Net Debt/EBITDA Net Debt/EBITDA Adi. 3M Avg Daily \$ Volume ROE 1 Year Chng Trailing EG/P Estimate Diffusion Avg. 12M Price Return & 1M Price.. EPS Variability (5yr) Trailing 5 Year EPS Growth EPS Estimate Dispersion (FY2) 3M Price Chg Operating Margin YoY Chg Beta (5yr) Dividend Growth Foreign Exposure Avg. 12M & 1M Price Return Long-term Growth Market Cap 1M Chg in 200 Day MA Forward FG/P 5Wk/30Wk MA 12M Price Chg ■ Leverage 30wk/75wk MA P/200MA 9M Price Chg Benchmark Book/Price ■ Risk 10Wk/40Wk MA Dividend Yield (Payers Only) ■ Momentum Dividend Payers/Nonpayers Earners/Nonearners ■ Liquidity Share Repurchase Net Debt/Equity Cash Sales/EV Deployment Operating Margin FCF/EV ■ Growth ROA EBITDA/EV ■ Valuation ROIC FCF ROA GARP Trailing E/P FCF Yield Cash Flow ROIC Quality Sales/Price Net Debt/Mkt Cap ■ Miscellaneous CFO/P

Source: FactSet, BofA US Equity & US Quant Strategy

Forward E/P

Source: FactSet, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

5

3-month (3m) factor performance

Price Volatilty (1yr)

30wk/75wk MA

12M Price Chg

Analyst Coverage

3M Avg Daily Volume

Short Interest Ratio

EPS Estimate Revision

1M Chg in 200 Day MA

Earnings Surprise

Estimate Diffusion

Russell 2000 (EW)

5Wk/30Wk MA

FY1 EPS Growth

ROF

Price

P/200MA

Book/Price ROE 1 Year Chng

FCF ROA

FCF/EV

Sales/EV

FCF Yield

ROA

ROIC

Sales/Price

EBITDA/EV

Trailing E/P

CFO/P

Market Cap

10Wk/40Wk MA

Net Debt/EBITDA Adj.

Net Debt/EBITDA

Net Debt/Equity

Cash Flow ROIC

Share Repurchase

Net Debt/Mkt Cap

Dividend Growth

Foreign Exposure

Dividend Payers

Operating Margin

Dividend Yield (Payers Only)

Forward EG/P

Forward F/P

Earners/Nonearners

EPS Variability (5yr)

3M Avg Daily \$ Volume

Trailing 5 Year EPS Growth

EPS Estimate Dispersion (FY2)

Trailing YoY EPS Growth

Long-term Growth

Trailing EG/P

9M Price Chg

Beta (5yr)

3M Price Chg

Short Interest 12M Z-Score

1M Trading Volume (Cumulative)

Avg. 12M Price Return & 1M Price.

Operating Margin YoY Chg

Avg. 12M & 1M Price Return

Trailing 5 Year Sales Growth

Exhibit 15: Q1 total returns (%) – 3m (2/29/24)

Best: Price Volatility (1yr) Worst: Dividend Yield (Payers only)

vidend Yield (Payers only)


Best: Lo

0 5 10 15 20 25 30 35

Exhibit 16: Q5 total returns (%) – 3m (2/29/24)

Best: Low Cash Flow ROIC Worst: Low trailing EG/P

Exhibit 17: Q1-Q5 total returns (%) – 3m (2/29/24) Best: Price Volatility (1yr) Worst: Cash Flow ROIC



Source: FactSet, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

■ Miscellaneous

Leverage

■ Risk

Benchmark

■ Momentum

Cash Deployment

■ Liquidity

■ Growth

■ Valuation

GARP

Quality

Source: FactSet, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Source: FactSet, BofA US Equity & US Quant Strategy



YTD factor performance

Exhibit 18: Q1 total returns (%) – YTD (2/29/24)


Best: Price Volatility (1yr) Worst: Dividend Yield (Payers Only)


Exhibit 19: Q5 total returns (%) – YTD (2/29/24)

Best: Low Cash Flow ROIC Worst: Neg. Estimate EPS
Revision

Exhibit 20: Q1-Q5 total returns (%) – YTD (2/29/24)

Best: EPS Estimate Revision Worst: Net Debt/Mkt Cap





-12 -6 0 6 12 18 Low Cash Flow ROIC Low Net Debt/Mkt Cap Low Sales/Price Low FCF ROA Low CFO/P Low ROIC Low Net Debt/Equity Low ROA Low Sales/EV Low FCF Yield Low Forward E/P Low EBITDA/EV Low FCF/EV Low ROE Low Trailing E/P Low Operating Margin Low Share Repurchase or Issuance Nonearners Dividend Nonpayers Low Beta (5yr) Low Book/Price Low Price Low 10Wk/40Wk MA Low P/200MA Low 12M Price Chg Low Forward EG/P Low 5Wk/30Wk MA Low Dividend Yield (Payers Only) Low 30wk/75wk MA Low Avg. 12M & 1M Price Return Low 9M Price Chg Low Trailing 5 Year Sales Growth Russell 2000 (EW) Low EPS Estimate Dispersion (FY2) Small Market Cap Leverage Low 1M Chg in 200 Day MA Low Trailing 5 Year EPS Growth ■ Benchmark Low Long-term Growth Low Short Interest Ratio Risk Low Foreign Exposure Low Trailing EG/P Low Price Volatilty (1vr) ■ Momentum Low 3M Price Chg Low EPS Variability (5yr) ■ Liquidity Low 3M Avg Daily \$ Volume Low Avg. 12M Price Return & 1M... Cash Deployment Low Short Interest 12M Z-Score Low Dividend Growth Low ROE 1 Year Chng ■ Growth Low Net Debt/EBITDA Adj. Low Analyst Coverage ■ Valuation Low FY1 EPS Growth Low Net Debt/EBITDA Low Trailing YoY EPS Growth GARP Low Operating Margin YoY Chg Neg. Earnings Surprise Quality Low 3M Avg Daily Volume Low Estimate Diffusion ■ Miscellaneous Low 1M Trading Volume... Neg. EPS Estimate Revision

Source: FactSet, BofA US Equity & US Quant Strategy


BofA GLOBAL RESEARCH

 $\textbf{Source:} \ \mathsf{FactSet}, \ \mathsf{BofA} \ \mathsf{US} \ \mathsf{Equity} \ \& \ \mathsf{US} \ \mathsf{Quant} \ \mathsf{Strategy}$

12-month (12m) factor performance

Exhibit 21: Q1 total returns (%) – 12m (2/29/24)

Best: Trailing 5 Year EPS Growth Worst: Foreign Exposure




Source: FactSet, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Exhibit 22: Q5 total returns (%) - 12m (2/29/24)

Best: Low Net Debt/Mkt Cap W**orst**: Low Operating Margin YoY Change




Source: FactSet, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Exhibit 23: Q1-Q5 total returns (%) – 12m (2/29/24)

Best: Earnings Surprise Worst: Net Debts/Mkt Cap




Source: FactSet, BofA US Equity & US Quant Strategy



Mid-cap factor performance

Last month

Exhibit 24: Q1 total returns (%) – 1m (2/29/24)
Best: 30wk/75wk MA Worst: Foreign Exposure



Source: FactSet, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Exhibit 25: Q5 total returns (%) – 1m (2/29/24)

Best: Low Dividend Yield (Payers only) **Worst**: Low 30wk/75wk MA




Source: FactSet, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Exhibit 26: Q1-Q5 total returns (%) - 1m (2/29/24)

Best: 30wk/75wk MA Worst: Book/Price



Source: FactSet, BofA US Equity & US Quant Strategy

March 2024

3m factor performance

Exhibit 27: Q1 total returns (%) – 3m (2/29/24) Best: 30wk/75wk MA Worst: Foreign Exposure




Exhibit 28: Q5 total returns (%) – 3m (2/29/24)

Best: Low Dividend Yield (Payers Only) Worst: Low Foreign Exposure





Exhibit 29: Q1-Q5 total returns (%) - 3m (2/29/24)

Best: 30wk/75wk MA Worst: Dividend Yield (Payers Only)

GLOBAL RESEARCH



Source: FactSet, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Source: FactSet, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Source: FactSet, BofA US Equity & US Quant Strategy


YTD factor performance

Exhibit 30: Q1 total returns (%) – YTD (2/29/24)

Best: Avg. 30wk/75wk MA Worst: Net Debt/Mkt Cap

Exhibit 31: Q5 total returns (%) – YTD (2/29/24)
Best: Low Dividend Yield (Payers Only) Worst: Low
30wk/75wk

Exhibit 32: Q1-Q5 total returns (%) – YTD (2/29/24)
Best: 30wk/75wk Worst: Dividend Yield (Payers Only)



12m factor performance

Exhibit 33: Q1 total returns (%) - 12m (2/29/24) Best: Cash Flow ROIC Worst: Net Debt/EBITDA




Exhibit 34: Q5 total returns (%) - 12m (2/29/24)

Best: Low Dividend Yield (Payers Only) Worst: Low Foreign





Exhibit 35: Q1-Q5 total returns (%) - 12m (2/29/24)

Best: Cash Flow ROIC Worst: Dividend Yield (Payers Only)

GLOBAL RESEARCH



Source: FactSet, BofA US Equity & US Quant Strategy

Source: FactSet, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Source: FactSet, BofA US Equity & US Quant Strategy


BofA GLOBAL RESEARCH

Small & mid factor group performance

1 Month (1M)

Exhibit 36: On a 1M basis, Liquidity was the top-performing long-factor for small caps while Cash Development was the worst-performing factor.

February long-factor total return performance (in ppt) by factor group within the Russell 2000 (dark blue bars) and Russell Midcap (light blue bars), as of 2/29/2024




Source: FactSet financial data and analytics, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Exhibit 37: Liquidity also saw the most positive long-short spreads in small caps (vs Momentum in mid caps) on a 1M basis

February top-bottom quintile total return performance (in ppt) by factor group within the Russell 2000 (dark blue bars) and Russell Midcap (light blue bars), as of 2/29/2024




Source: FactSet financial data and analytics, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

3 Months (3M)

Exhibit 38: On a 3M basis, Risk was the top-performing long- factor group for SMID caps, while Cash Development had the most negative spreads for small caps

Three-month long- factor total return performance (in ppt) by factor group within the Russell 2000 (dark blue bars) and Russell Midcap (light blue bars), as of 2/29/2024




Source: FactSet financial data and analytics, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Exhibit 39: On a 3M basis, Risk was the top-performing long-short factor group for small caps, while Value had the most negative spreads

Three-month top-bottom quintile total return performance (in ppt) by factor group within the Russell 2000 (dark blue bars) and Russell Midcap (light blue bars), as of 2/29/2024




Source: FactSet financial data and analytics, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Year to Date (YTD)

Exhibit 40: On a YTD basis, Momentum was the top-performing long-factor group for SMID caps, while Cash Development had the most negative spreads for small caps

YTD long- factor total return performance (in ppt) by factor group within the Russell 2000 (dark blue bars) and Russell Midcap (light blue bars), as of 2/29/2024




Source: FactSet financial data and analytics, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Exhibit 41: On a YTD basis, Liquidity was the top-performing long-short factor group for small caps, while Value was the worst

YTD top-bottom quintile total return performance (in ppt) by factor group within the Russell 2000 (dark blue bars) and Russell Midcap (light blue bars), as of 2/29/2024




Source: FactSet financial data and analytics, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

12 Months (12M)

Exhibit 42: On a 12M basis, Quality was the top-performing longfactor group for SMID caps, while Risk had the most negative spreads for small caps

Twelve-month long-factor total return performance (in ppt) by factor group within the Russell 2000 (dark blue bars) and Russell Midcap (light blue bars), as of 2/29/2024




Source: FactSet financial data and analytics, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH

Exhibit 43: On a 12M basis, Growth was the top-performing long-short factor for small caps, while Leverage was the worst

Twelve-month top-bottom quintile total return performance (in ppt) by factor group within the Russell 2000 (dark blue bars) and Russell Midcap (light blue bars), as of 2/29/2024



Source: FactSet financial data and analytics, BofA US Equity & US Quant Strategy

BofA GLOBAL RESEARCH



Methodology

The universe for this report is the Russell 2000 and Russell Midcap, excluding stocks priced under \$1. The universe and the factors are rebalanced monthly using month-end data. FactSet is used as the source of all data. A factor's return is calculated as the equal-weighted total return of the top quintile of stocks within the universe by that factor for Quintile 1 (Q1), the equal-weighted total return of the bottom quintile of stocks within the universe by that factor for Quintile 5 (Q5), and the equal-weighted total return of the top quintile minus the bottom quintile for the Q1-Q5 spread. We also show the total return of the equal-weighted Russell 2000 (for small caps) and Russell Midcap (for mid-caps) as the benchmark return. Performance results do not reflect actual transactions, and no assurances can be given about future performance.

Factor Definitions

Valuation Factors

Book/Price (Q1=highest): Common equity per share divided by price.

EBITDA/EV (Q1=highest): LTM (last 12 months) earnings before interest, taxes, depreciation and amortization divided by Enterprise Value (market cap + preferred stock + short term debt + long term debt + minority interest – cash). Financials are excluded.

Free Cash Flow Yield (Q1=highest): (LTM cash flow from operations – LTM capital expenditures) divided by market cap. Financials and Equity REITs are excluded.

Free Cash Flow/EV (Q1=highest): (LTM cash flow from operations – LTM capital expenditures) divided by Enterprise Value (market cap + preferred stock + short-term debt + long-term debt + minority interest – cash). Financials and Equity REITs are excluded.

Cash Flow/Price (CFO/P) (Q1=highest): LTM cash flow from operations divided by price. Financials and Equity REITs are excluded.

Forward E/P (Q1=highest): I/B/E/S FY1 EPS divided by price. FFO is used instead of EPS for Equity REITs.

Trailing E/P (Q1=highest): LTM EPS excluding extraordinary items divided by price. FFO is used instead of EPS for Equity REITs.

Sales/Price (Q1=highest): LTM sales per share divided by price. Financials are excluded.

Sales/EV (Q1=highest): LTM sales divided by enterprise value (market cap + preferred stock + short-term debt + long-term debt + minority interest – cash). Financials are excluded.

GARP (Growth at a Reasonable Price) Factors

Trailing EG/P (inverse of PEG) (Q1=highest): I/B/E/S long-term growth rate estimate divided by Trailing Earnings/Price.

Forward EG/P (inverse of PEG) (Q1=highest): I/B/E/S long-term growth rate estimate divided by Forward Earnings/Price.

Quality Factors

Return on Equity (ROE) (Q1=highest): LTM net income before extraordinary items divided by the one-year average of total stockholders' equity. Equity REITs are excluded.

ROE 1 year change (Q1=highest): 12 month change in ROE. Equity REITs are excluded.

Return on Assets (ROA) (Q1=highest): LTM net income before extraordinary items divided by the one-year average of total assets. Equity REITs are excluded.



Cash Flow ROIC (Cash flow return on invested capital) (Q1=highest): LTM cash flow from operations divided by invested capital (average common equity + average preferred equity + average long-term debt + average minority accumulated interest). Financials and Equity REITs are excluded.

Return on Invested Capital (ROIC) (Q1=highest): LTM net income before extraordinary items divided by the one-year average of total invested capital. Equity REITs are excluded.

Free Cash Flow Return on Assets (FCF ROA) (Q1=highest): (LTM cash flow from operations – LTM capital expenditures) divided by one-year average assets. Financials and Equity REITs are excluded.

Earners/Non-earners (Q1=earners, Q5=non-earners): Earners are stocks that have a positive forward (FY1) P/E; Non-earners are stocks with a negative forward (FY1) P/E. FFO is considered instead of EPS for Equity REITs.

Momentum Factors

Price to 200-Day Moving Average (Q1=highest): Ratio of the month-end closing price to the average closing price over the last 200 days.

- **1 Month Change in the 200-Day Moving Average (Q1=highest):** The 1-month change in the 200-day moving average.
- **5-week/30-week Moving Average (Q1=highest):** The ratio of the average daily closing price over the last five weeks vs. that over 30 weeks.
- **10-week/40-week Moving Average (Q1=highest):** The ratio of the average daily closing price over the last ten weeks vs. that over 40 weeks.
- **30-week/75-week Moving Average (Q1=highest):** The ratio of the average daily closing price over the last 30 weeks vs. that over 75 weeks.
- **12-Month Price Change (Q1=highest):** The change in the current price from 12 months ago.
- 9-Month Price Change (Q1=highest): The change in the current price from 9 months ago.
- **3-Month Price Change (Q1=highest):** The change in the current price from 3 months ago.

Average 12-month Price Return & 1-month Price Return: (Q1=highest): Equalweighted rank of stocks by (1) highest the price return over the last 12 months; and (2) the highest price return over the last one month.

Average 12-month Price Return & 1-month Price Reversal (Q1=highest): Equalweighted rank of stocks by (1) the highest price return over the last 12 months; and (2) the lowest price return over the last one month.

Growth Factors

IBES Mean LT Growth (Q1=highest): The mean estimate of I/B/E/S forecasted long-term growth rates.

EPS Estimate Revision (Q1=highest): The difference between the I/B/E/S FY1 EPS estimate that that of three months ago divided by the absolute value of the I/B/E/S FY1 EPS estimate as of three months ago. FFO is used instead of EPS for Equity REITs.

Estimate Diffusion (Q1=highest): Calculated using a three-month weighted-average of the change in the number of up estimates minus the down estimates divided by the total numbers of estimates for FY1. The most recent change in estimates received a weighting of 50%, the change from two months earlier was weighted at 30%, and the change from three months ago was allocated 20%. A company had to have at least two analysts covering it. FFO is used instead of EPS for Equity REITs.



Earnings Surprise (Q1=highest): The standardized unexpected earnings (SUE) score as determined by I/B/E/S, which is calculated by subtracting the mean earnings estimate by the actual reported earnings and then dividing that figure by the standard deviation of estimates. A company must have at least two analysts covering it to be included. FFO is used instead of EPS for Equity REITs.

Sales Growth Trailing 5 Year (Q1=highest): 5-year growth rate of trailing annual sales.

EPS Growth Trailing 5 Year (Q1=highest): 5-year growth rate of trailing annual diluted EPS. FFO is used instead of EPS for Equity REITs.

YoY Change in Trailing EPS (Q1=highest): Change in LTM EPS before extraordinary items from 4 quarters earlier LTM EPS before extraordinary items. FFO is used instead of EPS for Equity REITs.

FY1 EPS Growth (Q1=highest): Change in the FY1 EPS estimate versus the prior year actual (FY0) EPS. FFO is used instead of EPS for Equity REITs.

Operating Margin (Q1=highest): LTM operating income divided by LTM sales. Financials and Equity REITs are excluded.

Operating Margin Expansion (Q1=highest): 12-month change in operating margin. Financials and Equity REITs are excluded.

Risk Factors

EPS Variability (5-year) (Q1=highest): The degree of variability in quarterly EPS over the past five years. FFO is used instead of EPS for Equity REITs.

EPS Estimate Dispersion (FY2) (Q1=highest): The coefficient of variation among I/B/E/S FY2 EPS estimates (standard deviation of estimates divided by mean estimate). A stock must have at least two estimates available to be considered. FFO is used instead of EPS for Equity REITs.

Price Volatility (1yr) (Q1=highest): The standard deviation of the daily price change measured during the last year.

Beta (5yr) (Q1=highest): The regression coefficient from regressing monthly price returns against the returns of the S&P 500 over 60 months. Beta is a measure of non-diversifiable risk.

Liquidity Factors

- **3-Month Average Daily Volume (Q1=highest):** The average daily trading volume over the prior three months.
- **3-Month Average Daily Dollar Volume (Q1=highest):** The average daily trading dollar volume (volume times price) over the prior three months.
- **1-Month Trading Volume (Cumulative) (Q1=highest):** The cumulative trading volume over the past month.

Market Cap (Q1=highest): The month-end market capitalization.

Leverage Factors

Net Debt/Equity (Q1=highest): The total debt minus cash & short-term investments divided by total common equity. Financials are excluded.

Net Debt/Market Cap (Q1=highest): The total debt minus cash & short-term investments divided by total market capitalization. Financials are excluded.

Net Debt/EBITDA (Q1=highest): The total debt minus cash & short-term investments divided by operating EBITDA. Financials and companies with negative EBITDA are excluded.



Net Debt/EBITDA Adjusted (Q1=highest): The total debt minus cash & short-term investments divided by adjusted EBITDA (operating EBITDA + Unusual Expenses). Financials and companies with negative adjusted EBITDA are excluded.

Cash Deployment Factors

Dividend Growth (Q1=highest): The year-over-year growth between trailing four-quarter total common dividends as of the latest month-end and trailing four-quarter total common dividends as of 12 months ago.

Dividend Payers/Non-payer (Q1=Payers, Q5=Non-payers): Stocks that pay a dividend (based on the trailing 12-month dividend yield) are considered payers; stocks that don't pay a dividend are considered non-payers.

Dividend Yield (Payers only) (Q1=highest): Indicated dividend rate dividend by price. Companies that do not pay a dividend are excluded.

Share Repurchase (Q1=largest decrease in shares): Year-over-year change in shares outstanding.

Miscellaneous Factors

Price (Q1=highest): The month-end closing price.

Analyst Coverage (Q1=highest): The number of available I/B/E/S FY1 earnings estimates submitted by analysts.

Short Interest Ratio (Days to Cover) (Q1=highest): The number of shares held short divided by the average daily trading volume. It can be interpreted as the number of days it would take short sellers to cover the short position.

Short Interest 12M z-score (Q1=highest): The z-score of the most recent number of shares shorted vs. the last 12 months history.

Foreign Exposure (Q1=highest): The ratio of foreign sales to total sales.

US Regime Indicator methodology

Inputs for the US regime indicator include the following eight macroeconomic or topdown variables:

- Earnings Revision ratio: Calculated as the ratio (see our 1 January 2018 report) between the number of companies in the S&P 500 for which Thomson Financial consensus earnings estimates have been raised versus those that have been lowered. A rising ratio indicates an improving economic cycle.
- **ISM PMI:** ISM PMI Institute for Supply Management Manufacturing Purchasing Managers Index, represented as the Z-Score. The ISM Manufacturing Index monitors economic activity as reported by 300 supply management professionals. The reading of the index above (below) 50 indicated economic expansion (contraction).
- Inflation: The 12-month change in the BofA Inflation Composite (see methodology further below), represented as the Z-Score. Rising inflation indicates improving economic conditions.
- **GDP Forecast:** The next 12-month US GDP growth forecast from the Federal Reserve Bank of Philadelphia Survey, represented as the Z-Score.
- Leading Economic Indicators index: The 12-month change in the Conference Board US Leading Index of Ten Economic Indicators, represented as a Z-Score. A rising Z-Score indicates improving economic conditions.
- **US Capacity Utilization**: The 12-month change in US capacity utilization, represented as the Z-score. The capacity utilization rate indicates the percentage of



total economic capacity currently utilized. Rising capacity utilization implies improving economic conditions. Rising capacity utilization suggests more expanding economic cycle and potentially rising inflationary pressure.

- **10-year US Treasury Bond Yield**: The 12-month change in the bond yield, represented as the Z-Score. Rising yields indicate improving economic conditions.\
- **High Yield corporate bond credit spread**: The 12-month change in the US High Yield credit spread of the ICE BofA US High Yield Index, represented as a Z-score. Falling spreads indicate improving economic conditions.

Note on back-testing

The analysis of certain indicators in this report is back-tested and does not represent the actual performance of any account or fund. Back-tested performance depicts the hypothetical back-tested performance of a particular strategy over the time period indicated. In future periods, market and economic conditions will differ and the same strategy will not necessarily produce the same results. No representation is being made that any actual portfolio is likely to have achieved returns similar to those shown herein. In fact, there are frequently sharp differences between back-tested returns and the actual results realized in the actual management of a portfolio. Back-tested performance results are created by applying an investment strategy or methodology to historical data and attempts to give an indication as to how a strategy might have performed during a certain period in the past if the product had been in existence during such time. Backtested results have inherent limitations including the fact that they are calculated with the full benefit of hindsight, which allows the security selection methodology to be adjusted to maximize the returns. Further, the results shown do not reflect actual trading or the impact that material economic and market factors might have had on a portfolio manager's decision-making under actual circumstances. Back-tested returns do not reflect advisory fees, trading costs, or other fees or expenses.



Disclosures

Important Disclosures

FUNDAMENTAL EQUITY OPINION KEY: Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. VOLATILITY RISK RATINGS, indicators of potential price fluctuation, are: A - Low, B - Medium and C - High. INVESTMENT RATINGS reflect the analyst's assessment of both a stock's absolute total return potential as well as its attractiveness for investment relative to other stocks within its Coverage Cluster (defined below). Our investment ratings are: 1 - Buy stocks are expected to have a total return of at least 10% and are the most attractive stocks in the coverage cluster; 2 - Neutral stocks are expected to remain flat or increase in value and are less attractive than Buy rated stocks and 3 - Underperform stocks are the least attractive stocks in a coverage cluster. An investment rating of 6 (No Rating) indicates that a stock is no longer trading on the basis of fundamentals. Analysts assign investment ratings considering, among other things, the 0-12 month total return expectation for a stock and the firm's guidelines for ratings dispersions (shown in the table below). The current price objective for a stock should be referenced to better understand the total return expectation at any given time. The price objective reflects the analyst's view of the potential price appreciation (depreciation).

Investment rating Total return expectation (within 12-month period of date of initial rating) Ratings dispersion guidelines for coverage cluster^{R1}

 Buy
 ≥ 10%
 ≤ 70%

 Neutral
 ≥ 0%
 ≤ 30%

 Underperform
 N/A
 ≥ 20%

INCOME RATINGS, indicators of potential cash dividends, are: 7 - same/higher (dividend considered to be secure), 8 - same/lower (dividend not considered to be secure) and 9 - pays no cash dividend. Coverage Cluster is comprised of stocks covered by a single analyst or two or more analysts sharing a common industry, sector, region or other classification(s). A stock's coverage cluster is included in the most recent BofA Global Research report referencing the stock.

Due to the nature of strategic analysis, the issuers or securities recommended or discussed in this report are not continuously followed. Accordingly, investors must regard this report as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or securities.

Due to the nature of quantitative analysis, the issuers or securities recommended or discussed in this report are not continuously followed. Accordingly, investors must regard this report as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or securities.

BofA Global Research personnel (including the analyst(s) responsible for this report) receive compensation based upon, among other factors, the overall profitability of Bank of America Corporation, including profits derived from investment banking. The analyst(s) responsible for this report may also receive compensation based upon, among other factors, the overall profitability of the Bank's sales and trading businesses relating to the class of securities or financial instruments for which such analyst is responsible.

Other Important Disclosures

Prices are indicative and for information purposes only. Except as otherwise stated in the report, for any recommendation in relation to an equity security, the price referenced is the publicly traded price of the security as of close of business on the day prior to the date of the report or, if the report is published during intraday trading, the price referenced is indicative of the traded price as of the date and time of the report and in relation to a debt security (including equity preferred and CDS), prices are indicative as of the date and time of the report and are from various sources including BofA Securities trading desks.

The date and time of completion of the production of any recommendation in this report shall be the date and time of dissemination of this report as recorded in the report timestamp.

This report may refer to fixed income securities or other financial instruments that may not be offered or sold in one or more states or jurisdictions, or to certain categories of investors, including retail investors. Readers of this report are advised that any discussion, recommendation or other mention of such instruments is not a solicitation or offer to transact in such instruments. Investors should contact their BofA Securities representative or Merrill Global Wealth Management financial advisor for information relating to such instruments. Recipients who are not institutional investors or market professionals should seek the advice of their independent financial advisor before considering information in this report in connection with any investment decision, or for a necessary explanation of its contents.

Officers of BofAS or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments. Refer to BofA Global Research policies relating to conflicts of interest.

"BofA Securities" includes BofA Securities, Inc. ("BofAS") and its affiliates. Investors should contact their BofA Securities representative or Merrill Global Wealth Management financial advisor if they have questions concerning this report or concerning the appropriateness of any investment idea described herein for such investor. "BofA Securities" is a global brand for BofA Global Research.

Information relating to Non-US affiliates of BofA Securities and Distribution of Affiliate Research Reports:

BofAS and/or Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S") may in the future distribute, information of the following non-US affiliates in the US (short name: legal name, regulator): Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd., regulated by The Financial Service Board; MLI (UK): Merrill Lynch International, regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers (AMF). BofA Securities Europe SA ("BofASE") with registered address at 51, rue La Boétie, 75008 Paris is registered under no 842 602 690 RCS Paris. In accordance with the provisions of French Code Monétaire et Financier (Monetary and Financial Code), BofASE is an établissement de crédit et d'investissement (credit and investment institution) that is authorised and supervised by the European Central Bank and the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers. BofASE's share capital can be found at www.bofaml.com/BofASEdisclaimer; BofA Europe (Milan): Bank of America Europe Designated Activity Company, Milan Branch, regulated by the Bank of Italy, the European Central Bank (ECB) and the Central Bank of Ireland (CBI); BofA Europe (Frankfurt): Bank of America Europe Designated Activity Company, Frankfurt Branch regulated by BaFin, the ECB and the CBI; BofA Europe (Madrid): Bank of America Europe Designated Activity Company, Sucursal en España, regulated by the Bank of Spain, the ECB and the CBI; Merrill Lynch (Australia): Merrill Lynch (Hong Kong): Merr (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSFC); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch Canada Inc, regulated by the Canadian Investment Regulatory Organization; Merrill Lynch (Mexico): Merrill Lynch Mexico, SA de CV, Casa de Bolsa, regulated by the Comisión Nacional Bancaria y de Valores; BofAS Japan: BofA Securities Japan Co., Ltd., regulated by the Financial Services Agency; Merrill Lynch (Seoul): Merrill Lynch International, LLC Seoul Branch, regulated by the Financial Supervisory Service; Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd., regulated by the Securities and Futures Bureau; BofAS India: BofA Securities India Limited, regulated by the Securities and Exchange Board of India (SEBI); Merrill Lynch (Israel): Merrill Lynch Israel Limited, regulated by Israel Securities Authority; Merrill Lynch (DIFC): Merrill Lynch (DIFC): Merrill Lynch (DIFC): Merrill Lynch (DIFC): Merrill Lynch (Brazil): Mer Valores Mobiliários, regulated by Comissão de Valores Mobiliários; Merrill Lynch KSA Company: Merrill Lynch Kingdom of Saudi Arabia Company, regulated by the Capital Market Authority. This information: has been approved for publication and is distributed in the United Kingdom (UK) to professional clients and eligible counterparties (as each is defined in the rules of the FCA and the PRA) by MLI (UK), which is authorized by the PRA and regulated by the FCA and the PRA - details about the extent of our regulation by the FCA and PRA are available from us on request;



Ratings dispersions may vary from time to time where BofA Global Research believes it better reflects the investment prospects of stocks in a Coverage Cluster.

has been approved for publication and is distributed in the European Economic Area (EEA) by BofASE (France), which is authorized by the ACPR and regulated by the ACPR and the AMF; has been considered and distributed in Japan by BofAS Japan, a registered securities dealer under the Financial Instruments and Exchange Act in Japan, or its permitted affiliates; is issued and distributed in Hong Kong by Merrill Lynch (Hong Kong) which is regulated by HKSFC; is issued and distributed in Taiwan by Merrill Lynch (Taiwan); is issued and distributed in Singapore to institutional investors and/or accredited investors (each as defined under the Financial Advisers Regulations) by Merrill Lynch (Singapore) (Company Registration No 198602883D). Merrill Lynch (Singapore) is regulated by MAS. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 (MLEA) distributes this information in Australia only to 'Wholesale' clients as defined by s.761G of the Corporations Act 2001. With the exception of Bank of America N.A., Australia Branch, neither MLEA nor any of its affiliates involved in preparing this information is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this information in Brazil and its local distribution is by Merrill Lynch (Brazil) in accordance with applicable regulations. Merrill Lynch (DIFC) is authorized and regulated by the DFSA. Information prepared and issued by Merrill Lynch (DIFC) is done so in accordance with the requirements of the DFSA conduct of business rules. BofA Europe (Frankfurt) distributes this information in Germany and is regulated by BaFin, the ECB and the CBI. BofA Securities entities, including BofA Europe and BofASE (France), may outsource/delegate the marketing and/or provision of certain research services or aspects of research services to other branches or members of the BofA Securities group. You may be contacted by a d

This information has been prepared and issued by BofAS and/or one or more of its non-US affiliates. The author(s) of this information may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so. BofAS and/or MLPF&S is the distributor of this information in the US and accepts full responsibility for information distributed to BofAS and/or MLPF&S clients in the US by its non-US affiliates. Any US person receiving this information and wishing to effect any transaction in any security discussed herein should do so through BofAS and/or MLPF&S and not such foreign affiliates. Hong Kong recipients of this information should contact Merrill Lynch (Asia Pacific) Limited in respect of any matters relating to dealing in securities or provision of specific advice on securities or any other matters arising from, or in connection with, this information. Singapore recipients of this information should contact Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this information. For clients that are not accredited investors, expert investors or institutional investors Merrill Lynch (Singapore) Pte Ltd accepts full responsibility for the contents of this information distributed to such clients in Singapore.

General Investment Related Disclosures:

Taiwan Readers: Neither the information nor any opinion expressed herein constitutes an offer or a solicitation of an offer to transact in any securities or other financial instrument. No part of this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by the press or any other person without the express written consent of BofA Securities. This document provides general information only, and has been prepared for, and is intended for general distribution to, BofA Securities clients. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of, and is not directed to, any specific person(s). This document and its content do not constitute, and should not be considered to constitute, investment advice for purposes of ERISA, the US tax code, the Investment Advisers Act or otherwise. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this document.

Securities and other financial instruments referred to herein, or recommended, offered or sold by BofA Securities, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. Digital assets are extremely speculative, volatile and are largely unregulated. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

This report may contain a short-term trading idea or recommendation, which highlights a specific near-term catalyst or event impacting the issuer or the market that is anticipated to have a short-term price impact on the equity securities of the issuer. Short-term trading ideas and recommendations are different from and do not affect a stock's fundamental equity rating, which reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short-term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.

BofA Securities is aware that the implementation of the ideas expressed in this report may depend upon an investor's ability to "short" securities or other financial instruments and that such action may be limited by regulations prohibiting or restricting "shortselling" in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned herein. Investors in such securities and instruments, including ADRs, effectively assume currency risk.

BofAS or one of its affiliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. BofAS or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.

BofA Securities, through business units other than BofA Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented herein. Such ideas or recommendations may reflect different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Securities is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this information. In the event that the recipient received this information pursuant to a contract between the recipient and BofAS for the provision of research services for a separate fee, and in connection therewith BofAS may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom BofAS has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by BofAS). If such recipient uses the services of BofAS in connection with the sale or purchase of a security referred to herein, BofAS may act as principal for its own account or as agent for another person. BofAS is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities referred to herein.

Copyright and General Information:

Copyright 2024 Bank of America Corporation. All rights reserved. iQdatabase® is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Securities. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly-available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities. Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities have not been prepared as nor is disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving issuers mentioned in this material is based on public information. Facts and views presented in this material that relate to any such proceedings have not been

This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of BofAS any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.

Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to



seek tax advice based on their particular circumstances from an independent tax professional.

The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third-party websites. BofA Securities is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities. Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities ability to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.

Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.

In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofAS or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.

Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information.

